Invasive Lobular may benefit from personalized treatment...

Options
cp418
cp418 Member Posts: 7,079
edited June 2014 in Clinical Trials, Research News, Podcasts, and Study Results

http://www.sciencedaily.com/releases/2014/04/140404140209.htm

Common breast cancer subtype may benefit from personalized treatment approach

The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to new research. Invasive lobular carcinoma, characterized by a unique growth pattern in breast tissue that fails to form a lump, has distinct genetic markers which indicate drug therapies may provide benefits beyond those typically prescribed for the more common invasive ductal carcinoma.


· Share on FacebookShare on Twitter

Comments

  • hlya
    hlya Member Posts: 484
    edited April 2014

    wow, very interesting.  thanks for the link.

    sounds like Tamoxifen doesn't work for some ILC laddies.  Does it mean Tam doesn't work well for those without forming a lump?  Or do I misunderstand anything?

    · Share on FacebookShare on Twitter
  • wallycat
    wallycat Member Posts: 3,227
    edited April 2014

    I sent my oncologist the link and asked her if they are currently checking now.

    Here is what she emailed me back:

    I don’t think the testing to differentiate these subtypes are commonly
    used. Mainly in research studies now. For the time being, these tumors
    are all reported as “ER positive”, which with the testing we use, they
    are.

    The report also didn’t say there was NO
    benefit, just “less benefit”. And these are studies that are done on
    cell lines, not actual people. So they don’t really know, it is
    speculation based on the response to tamoxifen in cell lines.

    So not to worry ;-)

    · Share on FacebookShare on Twitter

Categories